Lifevantage Corp
LifeVantage is a nutrigenomics-focused company that identifies, researches, develops, formulates and sells dietary supplements and other wellness products to customers and independent consultants. It sells through a commission-based direct sales model, offering independent consultants commissions and a business opportunity. Its products are sold in the United States and multiple international markets. Its product lines include Protandim dietary supplements; LifeVantage supplements, including products for weight management, digestion and wellness; TrueScience skin and hair care products; the P84 System for gut health; Petandim supplements for dogs; and AXIO nootropic and energy and hydration drink mixes. LifeVantage also offers customer and consultant subscription programs, digital business tools and training resources. The company is headquartered in Lehi, Utah.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LFVN in the last 30 days.
See all $LFVN insider activity →LifeVantage (LFVN) announced a $0.05 per share quarterly dividend, matching its previous payout. The forward yield is 3.72%. The dividend is payable on December 15 to shareholders of record on December 1, with an ex-dividend date of December 1. The company also outlined a FY 2027 capex of $3M-$3.5M but withheld formal guidance due to a CEO transition.
LifeVantage reported Q1 Non-GAAP EPS of $0.05, missing estimates by $0.01, and revenue of $37.1M, missing by $3.39M. Revenue declined 22.1% year-over-year. Adjusted EBITDA fell to $1.9M from $3.9M a year ago. The company plans $3M-$3.5M in capex for FY 2027 but withheld formal guidance due to a CEO transition.
Lifevantage Corp (LFVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeVantage Announces Financial Results for the First Quarter Fiscal 2027 Salt Lake City, UT, November 9, 2026 , LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning LFVN (Lifevantage Corp). Coverage has skewed bearish: 0 bullish, 3 neutral, and 6 bearish.
Recent LFVN coverage spans earnings, corporate actions and financial news.
The dividend adds modest yield, likely supporting the stock modestly.
Earnings miss likely triggers short‑term downside pressure.
Earnings miss and loss likely trigger short-term price pressure.
Analysts and traders may adjust positions ahead of the earnings release based on the modest revenue and EPS guidance.
The grant increases potential dilution and signals confidence in long‑term growth, likely putting modest downward pressure on the stock.
AlphAI scores every news story that mentions LFVN with an AI model for sentiment and relevance, and aggregates insider trades from Lifevantage Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
LifeVantage (LFVN) announced a $0.05 per share quarterly dividend, matching its previous payout. The forward yield is 3.72%. The dividend is payable on December 15 to shareholders of record on December 1, with an ex-dividend date of December 1. The company also outlined a FY 2027 capex of $3M-$3.5M but withheld formal guidance due to a CEO transition.
LifeVantage reported Q1 Non-GAAP EPS of $0.05, missing estimates by $0.01, and revenue of $37.1M, missing by $3.39M. Revenue declined 22.1% year-over-year. Adjusted EBITDA fell to $1.9M from $3.9M a year ago. The company plans $3M-$3.5M in capex for FY 2027 but withheld formal guidance due to a CEO transition.
Lifevantage Corp (LFVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeVantage Announces Financial Results for the First Quarter Fiscal 2027 Salt Lake City, UT, November 9, 2026 , LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular
Lifevantage Corporation (LFVN) will report Q1'27 earnings on November 9. Analysts expect revenue of $40.49M and EPS of $0.06. Results will be released after market close at 4:00 PM ET.
LifeVantage (LFVN) granted CEO Terrence Moorehead 128,824 RSUs and 193,237 target PSUs, with the latter tied to revenue and Adjusted EBITDA margin over 3.5 years, under Nasdaq Rule 5635(c)(4).
Lifevantage Corporation (LFVN) shares fell 10.2% in after-hours trading to $5.79 after reporting Q4 and fiscal year 2026 results. Revenue declined 25.2% YoY in Q3, missing estimates, and earnings per share also missed. Institutional investors reduced positions, with BlackRock and Geode Capital Management cutting stakes significantly. The stock is down from its 52-week high of $14.28 but above its low of $3.90.
Lifevantage Corp (LFVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026 Salt Lake City, UT, August 27, 2026 , LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the c
BEINDORFF MICHAEL A sold 10,000 indirectly-held shares of Lifevantage Corp (LFVN) at $8.55 on 2026-06-03.
LifeVantage (Nasdaq: LFVN) announced that CEO Steve Fife will retire in April 2026 after nine years with the company. Fife will remain in his role during a transition period while the Board conducts an executive search. Following this news, LFVN's stock declined 27.21%, reflecting market concerns about leadership uncertainty.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
